The placebo response in functional bowel disorders: perspectives and putative mechanisms

被引:86
作者
Enck, P
Klosterhalfen, S
机构
[1] Univ Tubingen Hosp, Dept Internal Med Psychosomat 6, D-72072 Tubingen, Germany
[2] Univ Hosp Dusseldorf, Inst Med Psychol, Dusseldorf, Germany
关键词
clinical trials; functional bowel disorders; placebo response;
D O I
10.1111/j.1365-2982.2005.00676.x
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
The nature and determinants of the placebo response are widely unknown, as are the underlying psychological and biological mechanisms. High placebo response rates in functional bowel disorders (functional dyspepsia, irritable bowel syndrome) are similar to those in non-intestinal diseases (depression, pain, Parkinson's disease) and not too dissimilar to other organic gastrointestinal diseases (duodenal ulcer, inflammatory bowel diseases). Methodological reasons (regression to the mean, shift in signal detection through manipulation of expectations) and psycho-biological mechanisms (Pavlovian conditioning of biological processes) are proposed to explain a large component of the response variance in clinical trials. Psychobiological mechanisms of the placebo response in functional and organic diseases can also be identified in brain function studies (such as imaging).
引用
收藏
页码:325 / 331
页数:7
相关论文
共 45 条
[1]   Treatment of non-ulcer dyspepsia:: a meta-analysis of placebo-controlled prospective studies [J].
Allescher, HD ;
Böckenhoff, A ;
Knapp, G ;
Wienbeck, M ;
Hartung, J .
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 2001, 36 (09) :934-941
[2]   Placebo response in depression: bane of research, boon to therapy [J].
Andrews, G .
BRITISH JOURNAL OF PSYCHIATRY, 2001, 178 :192-194
[3]  
Aulas JJ, 2003, ENCEPHALE, V29, P68
[4]   Placebo-responsive Parkinson patients show decreased activity in single neurons of subthalamic nucleus [J].
Benedetti, F ;
Colloca, L ;
Torre, E ;
Lanotte, M ;
Melcarne, A ;
Pesare, M ;
Bergamasco, B ;
Lopiano, L .
NATURE NEUROSCIENCE, 2004, 7 (06) :587-588
[5]  
Benedetti F, 2003, J NEUROSCI, V23, P4315
[6]   Blockade of nocebo hyperalgesia by the cholecystokinin antagonist proglumide [J].
Benedetti, F ;
Amanzio, M ;
Casadio, C ;
Oliaro, A ;
Maggi, G .
PAIN, 1997, 71 (02) :135-140
[7]   Condition-specific deactivation of brain regions by 5-HT3 receptor antagonist Alosetron [J].
Berman, SM ;
Chang, L ;
Suyenobu, B ;
Derbyshire, SW ;
Stains, J ;
Fitzgerald, L ;
Mandelkern, M ;
Hamm, L ;
Vogt, B ;
Naliboff, BD ;
Mayer, EA .
GASTROENTEROLOGY, 2002, 123 (04) :969-977
[8]   Long-term safety and efficacy of alosetron in women with severe diarrhea-predominant irritable bowel syndrome [J].
Chey, WD ;
Chey, WY ;
Heath, AT ;
Dukes, GE ;
Carter, EG ;
Northcutt, A ;
Ameen, VZ .
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2004, 99 (11) :2195-2203
[9]   Efficacy of alosetron in irritable bowel syndrome: a meta-analysis of randomized controlled trials [J].
Cremonini, F ;
Delgado-Aros, S ;
Camilleri, M .
NEUROGASTROENTEROLOGY AND MOTILITY, 2003, 15 (01) :79-86
[10]   Placebo effect in the treatment of duodenal ulcer [J].
de Craen, AJM ;
Moerman, DE ;
Heisterkamp, SH ;
Tytgat, GNJ ;
Tijssen, JGP ;
Kleijnen, J .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1999, 48 (06) :853-860